Dissecting Tumor-Stromal Interactions in Breast Cancer Bone Metastasis.
10.3803/EnM.2016.31.2.206
- Author:
Yibin KANG
1
Author Information
1. Department of Molecular Biology, Princeton University, Princeton, NJ, USA. ykang@princeton.edu
- Publication Type:Review
- Keywords:
Breast neoplasms;
Bone metastasis;
Tumor-stromal interaction;
Osteoblasts;
Osteoclasts;
Transforming growth factor beta
- MeSH:
Biomarkers;
Bone Matrix;
Breast Neoplasms*;
Breast*;
Diagnosis;
Exosomes;
Fractures, Bone;
Humans;
Hypercalcemia;
MicroRNAs;
Neoplasm Metastasis*;
Osteoblasts;
Osteoclasts;
Stromal Cells;
Transforming Growth Factor beta;
Transforming Growth Factors;
Vascular Cell Adhesion Molecule-1
- From:Endocrinology and Metabolism
2016;31(2):206-212
- CountryRepublic of Korea
- Language:English
-
Abstract:
Bone metastasis is a frequent occurrence in breast cancer, affecting more than 70% of late stage cancer patients with severe complications such as fracture, bone pain, and hypercalcemia. The pathogenesis of osteolytic bone metastasis depends on cross-communications between tumor cells and various stromal cells residing in the bone microenvironment. Several growth factor signaling pathways, secreted micro RNAs (miRNAs) and exosomes are functional mediators of tumor-stromal interactions in bone metastasis. We developed a functional genomic approach to systemically identified molecular pathways utilized by breast cancer cells to engage the bone stroma in order to generate osteolytic bone metastasis. We showed that elevated expression of vascular cell adhesion molecule 1 (VCAM1) in disseminated breast tumor cells mediates the recruitment of pre-osteoclasts and promotes their differentiation to mature osteoclasts during the bone metastasis formation. Transforming growth factor β (TGF-β) is released from bone matrix upon bone destruction, and signals to breast cancer to further enhance their malignancy in developing bone metastasis. We furthered identified Jagged1 as a TGF-β target genes in tumor cells that engaged bone stromal cells through the activation of Notch signaling to provide a positive feedback to promote tumor growth and to activate osteoclast differentiation. Substantially change in miRNA expression was observed in osteoclasts during their differentiation and maturation, which can be exploited as circulating biomarkers of emerging bone metastasis and therapeutic targets for the treatment of bone metastasis. Further research in this direction may lead to improved diagnosis and treatment strategies for bone metastasis.
